These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2019-003622-25 A Phase 2, Open label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) 2020-10-02 due-trials
Completed, but no date, and reported results Terminated 2020-001663-90 An Open label, Compassionate Use Study of Tenalisib (RP6530) in Patients currently receiving treatment on Tenalisib trials in Hematological Malignancies bad-data